Drug intelligence / Profile preview

dpa-714 (Bayer)

Development stage
Preclinical
Lead developer
Bayer
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

DPA-714 is a small molecule ligand that specifically binds to the translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor. It is commonly radiolabeled with fluorine F 18 to create a PET imaging agent (fluorine F 18-DPA-714 or [18F]DPA-714) for detecting TSPO-expressing cells in vivo. TSPO is upregulated in various pathological conditions, particularly neuroinflammation and activated macrophages. DPA-714 has high affinity for TSPO and stimulates pregnenolone synthesis. The compound has been used primarily as a biomarker for neuroinflammation and in research settings to image inflammation associated with diseases such as Alzheimer's disease, epilepsy, rheumatoid arthritis, and brain tumors using positron emission tomography (PET)[1][3][4][5][6][7].

Other names
fluorine F 18-DPA-714
02

Targets

TSPO (Translocator Protein (18 kDa))

Beyond the preview

Go deeper on dpa-714 (Bayer).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dpa-714 (Bayer).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call